Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Should You Buy?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $3.51, but opened at $3.72. Autolus Therapeutics shares last traded at $3.53, with a volume of 393,016 shares changing hands.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC restated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a report on Monday.

Autolus Therapeutics Stock Performance

The firm has a 50 day moving average price of $3.98 and a 200-day moving average price of $4.00. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $904.71 million, a PE ratio of -3.03 and a beta of 2.04.

Institutional Trading of Autolus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. HealthInvest Partners AB increased its position in shares of Autolus Therapeutics by 95.6% during the third quarter. HealthInvest Partners AB now owns 442,423 shares of the company’s stock worth $1,606,000 after acquiring an additional 216,278 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Autolus Therapeutics during the 3rd quarter valued at $1,082,000. Privium Fund Management B.V. boosted its holdings in Autolus Therapeutics by 15.6% in the third quarter. Privium Fund Management B.V. now owns 185,639 shares of the company’s stock worth $674,000 after purchasing an additional 25,000 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after acquiring an additional 14,959 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its position in shares of Autolus Therapeutics by 9.8% during the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock valued at $152,000 after buying an additional 3,740 shares during the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.